Fennec Pharmaceuticals Q3 2023 Earnings Report $5.59 -0.35 (-5.89%) As of 04:00 PM Eastern Earnings HistoryForecast Fennec Pharmaceuticals EPS ResultsActual EPS-$0.07Consensus EPS -$0.11Beat/MissBeat by +$0.04One Year Ago EPS-$0.31Fennec Pharmaceuticals Revenue ResultsActual Revenue$6.52 millionExpected Revenue$5.22 millionBeat/MissBeat by +$1.30 millionYoY Revenue GrowthN/AFennec Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/6/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseFENC Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Fennec Pharmaceuticals Earnings HeadlinesFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comFennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...March 11, 2025 | gurufocus.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Q4 2024 Fennec Pharmaceuticals Inc Earnings Call TranscriptMarch 11, 2025 | gurufocus.comFennec Pharmaceuticals Shares Down After 4Q ResultsMarch 10, 2025 | marketwatch.comInvesting in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gainMarch 10, 2025 | finance.yahoo.comSee More Fennec Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email. Email Address About Fennec PharmaceuticalsFennec Pharmaceuticals (NASDAQ:FENC)., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.View Fennec Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
